AKR1B10作为一种潜在的新型乳腺癌血清生物标志物：一项初步研究。
AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot Study.
作者信息
Cao Zhe, Delfino Kristin, Tiwari Vivek, Wang Xin, Hannan Abdul, Zaidi Fawwad, McClintock Andrew, Robinson Kathy, Zhu Yun, Gao John, Cao Deliang, Rao Krishna
机构信息
Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Department of Medical Microbiology, Immunology and Cell Biology, Simmons Cancer Institute, Southern Illinois University School of Medicine, Springfield, IL, United States.
出版信息
Front Oncol. 2022 Feb 24;12:727505. doi: 10.3389/fonc.2022.727505. eCollection 2022.
BACKGROUND
Aldo-keto reductase 1B10 (AKR1B10) is a secretory protein that is upregulated in breast cancer.
OBJECTIVE
This case-controlled pilot study evaluated the serum level of AKR1B10 in healthy women and patients with a localized or metastatic breast cancer.
METHODS
AKR1B10 levels were measured by ELISA and IHC in several patient cohorts.
RESULTS
Our data showed that serum AKR1B10 was significantly elevated in patients with localized (6.72 ± 0.92 ng/ml) or metastatic (7.79 ± 1.13 ng/ml) disease compared to cancer-free healthy women (1.69 ± 0.17 ng/ml) (p<0.001); the serum AKR1B10 was correlated with its expression in tumor tissues, but not with the tumor burden, molecular subtypes or histological stages. After surgical removal of primary tumors, the serum AKR1B10 was rapidly decreased within 3 days and plateaued at a level similar to that of healthy controls in most patients. ROC curve analysis suggested the optimal diagnostic cut-off value of serum AKR1B10 at 3.456 ng/ml with AUC 0.9045 ± 0.0337 (95% CI 0.8384 - 0.9706), sensitivity 84.75% (95% CI 73.01% to 92.78%), and specificity 93.88% (95% CI 83.13% to 98.72%).
CONCLUSIONS
These data indicate the potential value of serum AKR1B10 as a biomarker of breast cancer.
背景
醛酮还原酶1B10（AKR1B10）是一种在乳腺癌中上调的分泌蛋白。
目的
本病例对照试验研究评估了健康女性以及局限性或转移性乳腺癌患者血清中AKR1B10的水平。
方法
通过酶联免疫吸附测定（ELISA）和免疫组织化学（IHC）检测了多个患者队列中的AKR1B10水平。
结果
我们的数据显示，与无癌健康女性（1.69±0.17纳克/毫升）相比，局限性疾病患者（6.72±0.92纳克/毫升）或转移性疾病患者（7.79±1.13纳克/毫升）的血清AKR1B10显著升高（p<0.001）；血清AKR1B10与其在肿瘤组织中的表达相关，但与肿瘤负荷、分子亚型或组织学分期无关。手术切除原发性肿瘤后，多数患者血清AKR1B10在3天内迅速下降，并稳定在与健康对照相似的水平。ROC曲线分析表明，血清AKR1B10的最佳诊断临界值为3.456纳克/毫升，曲线下面积（AUC）为0.9045±0.0337（95%可信区间0.8384 - 0.9706），灵敏度为84.75%（95%可信区间73.01%至92.78%），特异性为93.88%（95%可信区间83.13%至98.72%）。
结论
这些数据表明血清AKR1B10作为乳腺癌生物标志物的潜在价值。
Zotero 插件